The Phase 1 study is a randomized, double-blind, placebo-controlled, dose-escalation trial carried out in China, designed to evaluate the safety, tolerability, pharmacokinetics (PK), and ...
AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...
Researchers sought to determine the acute cardiovascular effects of amphetamine-dextroamphetamine use in healthy people free of ADHD. Study volunteers showed increases in blood pressure, heart rate, ...
This study presents valuable findings implicating nuclear export in the regulation of protein condensate behaviour and TDP-43 phase behaviour, suggesting a link to pathogenic aggregation in ALS/FTD.
Hello Dose introduces the DROP™ Method, a structured four-step framework designed to support clinician-supervised GLP-1 medication management with behavioral and educational guidance.
CEO Todd Harris said the company has narrowed its focus to what he described as the “highest value opportunities” for its selective FGFR3 inhibitor dabogratinib, emphasizing indications where FGFR3 ...
Load epilepsy, where a substantial proportion of patients remain drug resistant despite multiple anti-seizure medications, ...
Understand the significance of proteo-transcriptomics in identifying vulnerabilities in Candida auris and addressing drug resistance.
Animal health company Zoetis and Neogen Corporation, a food and animal safety solution provider, have entered into a definitive acquisition agreement. Under the $160 million deal, Zoetis will acquire ...
Healthcare technology companies DoseSpot and Arrive Health have merged to combine an electronic prescribing platform with medical and pharmacy benefits data to advance real-time medication price tr | ...
Background: Online gambling and sports betting have recently been legalized and expanded in North America. We aimed to evaluate long-term changes in the frequency of gambling-related helpline contacts ...